Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 Early-career researchers ... , Peru , Uganda and ... life-enhancing work in health and nutrition   Indonesia ... Uganda and Yemen are being ... and epidemiology. They are also celebrated for mentoring young women scientists who ...
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... plc (NYSE: AGN ) a leading global pharmaceutical ... CEO and President, will be featured as the keynote ... Capital Markets Healthcare Conference on Tuesday, February 23, 2016 ... Hotel in New York, NY . ... accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... MO (PRWEB) , ... February 10, 2016 , ... ... will attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st ... ISPE is expecting to fill more than 100 tables for its annual event, ...
Breaking Biology Technology:
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. ... developer of innovative sensor-based diagnostic products, today announced the closing ... new and existing investors.  Proceeds from the financing will be ... , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The device,s ...
Breaking Biology News(10 mins):